1. Introduction {#sec1-antibiotics-08-00114}
===============

Antimicrobial resistance and transmission of drug resistance complicate management of infections. Thus, hospitalization and mortality rates are increasing. Moreover, antimicrobial therapy becomes even more complicated due to limited treatment options \[[@B1-antibiotics-08-00114]\].

In order to prevent and overcome emerging drug resistance, antimicrobial combination therapy is a rational approach. Synergistic interactions among drugs provide a huge benefit for treatment. However, some risks should be considered, since some of the antibiotics might have antagonistic interactions. Therefore, drug interactions should be carefully evaluated.

Bacterial infections are estimated at over 250 million infections per year and they are causing around \$1.6 billion in economic losses each year. Emerging antimicrobial resistance and transmission of resistance among the strains complicates the management of the infection and it increases the rate of hospitalization and mortality. In addition, among patients with underlying secondary diseases antimicrobial drug therapy is even more complicated \[[@B2-antibiotics-08-00114]\].

Combination therapies based on antibiotic interactions may be used to slow down resistance evolution and increase the potency of drugs. Two or more drugs can interact to result in a different efficacy compared to the independent use of a single drug. If the interaction results in a decreased efficacy, the drugs show antagonism. An increase in efficacy as a result of drug interaction is called synergy. Antagonistic drug pairs gained relevance in the field of antibiotic resistance, as resistant colonies were shown to be selected against when treated with hyper-antagonistic antibiotic combinations \[[@B3-antibiotics-08-00114]\] and it has been suggested that the risk of evolution of resistance to both drugs may be decreased in antagonistic pairs \[[@B4-antibiotics-08-00114]\]. Synergistic drug pairs can enhance therapeutic value and overcome toxicity by allowing lower doses \[[@B5-antibiotics-08-00114]\]. Despite giving resistant cells a selective advantage, synergy may also help prevent the evolution of drug resistance by minimizing the clearance rate of infection, when competition for resources is weak \[[@B6-antibiotics-08-00114]\]. Another important prevention method is avoiding transmission of resistant pathogenic bacteria. Thus, hand washing is the simplest, cheapest, and the most powerful method. Disinfection of tools and environment is another powerful prevention method against transmission of pathogenic bacteria \[[@B7-antibiotics-08-00114],[@B8-antibiotics-08-00114],[@B9-antibiotics-08-00114]\].

In this study, we aimed to evaluate interactions of the combinations of protein and nucleic acid synthesis inhibitors which are shown in [Table 1](#antibiotics-08-00114-t001){ref-type="table"} with mechanisms of action. Understanding the importance of mechanisms of action of drugs in antibiotic interactions is crucial for better selection of drug combinations. Studies of screening interactions of pairwise combinations of nucleic acid synthesis and protein synthesis inhibitors will shed light on finding more effective drug pairs in therapy.

2. Materials and Methods {#sec2-antibiotics-08-00114}
========================

Bacterial Strain and Culture: *E. coli* is one of the most abundant bacteria in human flora and the potential of its infection risk is high. Thus, model bacteria ATCC 10798 (Lambda+), *E. coli*, were used in this study. Glycerol stocks were prepared and stored at −20 °C. Bacteria were plated on LB (Luria--Bertani) agar for colony formation prior to preparation of the starter cultures. Colonies were picked and grown in LB overnight for MIC (Minimum Inhibitory Concentration) and interaction experiments.

Study Design: Drug interaction experiments were done by using a 4 × 4 checkerboard assay \[[@B10-antibiotics-08-00114]\]. Accordingly, the concentration of each drug used in the assay increased gradually in each axis with a starting drug concentration of zero (no drug). Protein and nucleic acid synthesis inhibitor drugs are the main classes for treatment of pathogenic bacteria and it is important to find potent synergistic pairs between these two main antibiotic classes in order to have better treatment options. Therefore, these two main classes were selected for the study. Bacteria were grown in LB media and treated with the combinations of eleven protein synthesis and six nucleic acid synthesis inhibitor antibiotics shown in [Table 1](#antibiotics-08-00114-t001){ref-type="table"}. End-point optical density (OD, 600 nm) measurements using a 96-well microplate reader were done at the end of overnight incubation.

In drug interaction experiments, each individual drug was used at the concentration that was \>50% inhibition at the highest dose and \<50% inhibition at the lowest dose, as detailed in a previous study \[[@B10-antibiotics-08-00114],[@B11-antibiotics-08-00114]\]. All drugs were purchased from Sigma. Simple two-fold dilution assay was used for MICs for each drug shown in [Table 1](#antibiotics-08-00114-t001){ref-type="table"}.

Statistics: Interactions were quantified based on the isophenotypic growth contour method described in Cokol et al. \[[@B2-antibiotics-08-00114]\] based on the Loewe additivity model \[[@B12-antibiotics-08-00114]\]. The growth contour was linear for drugs that were non-interacting. Depending on the concavity or convexity of the growth contour, interactions were classified as synergistic or antagonistic. The Null hypothesis according to Loewe's interaction model was that a drug was non-interacting with itself. Deviations from this null model meant either synergy or antagonism.

Statistical analysis was performed with SPSS version 20.0 for Windows. Comparisons of alpha scores of drug combinations were performed with the Mann---Whitney U test between groups. A value of *p* \< 0.05 was considered statistically significant.

3. Results {#sec3-antibiotics-08-00114}
==========

Pairwise combinations of the eleven protein and six nucleic acid synthesis inhibitor antibiotics, with MIC values shown in [Table 1](#antibiotics-08-00114-t001){ref-type="table"}, were used in in order to evaluate drug interaction patterns. Combinations of nucleic acid synthesis inhibitor antibiotics (NN) namely, Ciprofloxacin (CIP, 0.05 µg/mL MIC), Levofloxacin (LEV, 0.01 µg/mL MIC), Nalidixic acid (NAL, 8 µg/mL MIC), Trimethoprim (TRI, 1.5 µg/mL MIC), Rifampicin (RIF, 0.5 µg/mL MIC), and 5-Fluorouracil (5-FU, 2 µg/mL MIC), combinations of protein synthesis inhibitor antibiotics (PP) namely, Amikacin (AMK, 13 µg/mL MIC), Gentamicin (GEN, 7 µg/mL MIC), Tobramycin (TOB, 0.7 µg/mL MIC), Tetracycline (TET, 5 µg/mL MIC), Chloramphenicol (CHL, 3.5 µg/mL MIC), Clarithromycin (CLA, 9 µg/mL MIC), Erythromycin (ERY, 15 µg/mL MIC), Fusidic acid (FUS, 80 µg/mL MIC), Spectinomycin (SPE, 2 µg/mL MIC), Roxithromycin (ROX, 0.3 µg/mL MIC), and Mupirocin (MUP, 0.4 µg/mL MIC), and pairwise combinations of both protein synthesis and nucleic acid synthesis inhibitor antibiotics were evaluated. In total, 136 pairwise drug combinations were used which consisted of the 55 PP, 15 NN, and 66 PN antimicrobial combinations shown in [Table 2](#antibiotics-08-00114-t002){ref-type="table"}. Statistical analysis demonstrated in [Table 2](#antibiotics-08-00114-t002){ref-type="table"} showed that combinations of protein synthesis inhibitors (PP) were more prone to showing synergistic interactions than those of nucleic acid synthesis inhibitors (NN) and the combination of nucleic acid synthesis--protein synthesis inhibitors (PN). In [Table 2](#antibiotics-08-00114-t002){ref-type="table"}, PP--NN, PN--NN, and PN--PP pairwise drug combinations are statistically compared according to their alpha scores in order to demonstrate which class of inhibitors showed a more synergistic or antagonistic manner. According to *p* values, PP combinations were more prone to demonstrate synergistic interactions, as partially shown in previous studies \[[@B10-antibiotics-08-00114]\].

[Figure 1](#antibiotics-08-00114-f001){ref-type="fig"} shows distributions of alpha values of pairwise drug combinations, which represent synergistic or antagonistic interactions. Negative values show synergistic interactions whereas positive values represent antagonistic interactions of combinations of protein synthesis inhibitors (PP), nucleic acid synthesis inhibitors (NN), and combinations of both nucleic acid synthesis and protein synthesis inhibitors (PN). Positive alpha scores or antagonistic interactions are more likely to occur between PN and NN combinations compared to PP drug combinations.

According to statistical analysis demonstrated in [Table 2](#antibiotics-08-00114-t002){ref-type="table"}, combinations of protein synthesis inhibitors (PP) showed stronger synergistic interactions than those of nucleic acid synthesis inhibitors (NN) and the combination of nucleic acid synthesis--protein synthesis inhibitors (PN).

4. Discussion {#sec4-antibiotics-08-00114}
=============

Multidrug resistance of bacteria against antimicrobials is a dangerous problem. Combination therapy is a commonly used treatment option especially for serious infections to provide synergistic effects, combat antibiotic resistance, reduce treatment time, and widen the therapeutic spectrum \[[@B13-antibiotics-08-00114]\].

Drug interactions have become of remarkable scientific interest. Different classes of antibiotics were evaluated in previous studies conducted on different species such as *Klebsiella* sp. \[[@B14-antibiotics-08-00114],[@B15-antibiotics-08-00114],[@B16-antibiotics-08-00114]\]. In this study, 136 pairwise drug combinations, which consisted of 55 PP, 15 NN, and 66 PN antimicrobial combinations were evaluated shown in [Table 3](#antibiotics-08-00114-t003){ref-type="table"}. Several studies of synergistic and antagonistic drug interactions of antibiotic combinations in pathogenic species have been published. In comparison with this study, previous results from other studies have shown similar drug interactions. Our results are supported by previous findings. \[[@B16-antibiotics-08-00114],[@B17-antibiotics-08-00114]\]. However, there are still a small number of studies in the literature that show categorical and systematic evaluation of antibiotic molecules with different modes of action. There were some studies that showed some of the drug interactions between protein synthesis inhibitors \[[@B14-antibiotics-08-00114],[@B17-antibiotics-08-00114]\] in wild-type laboratory strains. Accordingly, our results are in parallel with previous findings of those studies. In our study, combinations of protein synthesis inhibitors tended to be more likely to show synergistic interaction patterns than PN and NN pairwise drug combinations. Chandrasekaran et al. evaluated pairwise drug combinations between 15 different drugs that belong to different antibiotic classes, including cell wall inhibitors. Out of 105 combinations only 14 demonstrated synergistic interactions. In our study synergistic combinations were also found in limited numbers. According to Chandrasekaran et al., out of the 14 synergistic drug interactions found, nearly half were between protein synthesis inhibitors. These findings support this present study. As shown in [Table 2](#antibiotics-08-00114-t002){ref-type="table"}, PP drug combinations were more likely to show synergistic drug interactions than NN and PN drug combinations, especially, among protein synthesis inhibitors namely Tetracycline, Chloramphenicol, Erythromycin, and Clarithromycin, which were demonstrated in a similar manner by Chandrasekaran et al.

There are theoretical explanations for drug interaction models. One explanation is that drugs may show synergy if a drug's action helps a second drug's availability in the cell. This is called the bioavailability model. According to the bioavailability model, two compounds might form a more potent compound and this would affect different target sites, or a compound might facilitate another compound's transportation through the cellular membrane \[[@B18-antibiotics-08-00114]\]. Another explanation is the physical interaction model that two drugs physically interact to make a more potent compound. Another is the same target model that two drugs may be synergistic if they target different sites on the same protein or a target. This suggests that protein synthesis inhibitors, especially those that have the same targets (30S or 50S subunits, etc.) might be more likely to show synergistic interactions. In our study, PP combinations expectedly showed more synergistic interactions, unlike NN combinations. Even if NN combinations had drug pairs with same targets, they did tend to show more additive or antagonistic interactions compared to PP and PN combinations according to statistical analysis between pairwise combinations of different antibiotic classes. This suggests that combinations might have drug pairs with the same targets, but still tend to show antagonistic interactions. According to the drug antagonism model, antagonism occurs when a drug's action impedes the metabolism of the cell so that the second drug cannot achieve its optimal effect. Some of the antagonistic interactions in our study might be explained by using this model especially for PP and NN combinations.

A systematic exploration of drug interactions was achieved in the context of mechanisms of action of drug molecules. In a previous study, a systematic exploration of antifungal drugs was done. According to the results, antagonistic drug interactions were more likely, compared to synergistic drug interactions \[[@B2-antibiotics-08-00114]\]. Although, synergistic interactions were seen in limited numbers, our results show that PP combinations are a better choice compared to PN and NN combinations in terms of providing synergistic drug pairs. Mechanisms of action of drug molecules seem to be critical for their potency in combinatorial use \[[@B4-antibiotics-08-00114]\]. In accordance with the study of Yeh et al., our results clearly show drug classes rule the type of pairwise drug interaction model. In this study, there are interesting points that should be further investigated. Out of eighteen synergistic combinations, eight contained 5-fluorouracil in pairwise combinations. In the PP combinations twelve out of a total of twenty-six synergistic combinations contained a macrolide antibiotic. However, some macrolides did not synergize with some compounds which have similar targets. For instance, AMK is synergistic with CLA, but is not synergistic with ROX or ERY.

Another important discussion point is understanding of the synergistic or antagonistic response in various bacterial genetic backgrounds. In this study, we used the ATCC 10798 strain which has the Lambda+ genotype. This strain might have an SOS response which might be induced especially by nucleic acid synthesis inhibitors such as 5-fluorouracil \[[@B19-antibiotics-08-00114],[@B20-antibiotics-08-00114]\]. It is known that induction of the SOS response may induce the lytic phage cycle. This could in turn affect the MIC value of single compound therapy and may affect combinatorial drug treatment. In addition, the lytic cycle requires production of new proteins and DNA. Under treatment with a protein synthesis inhibitor, the lytic cycle might be affected in a combinatorial therapy and drug interaction types may differ.

5. Conclusions {#sec5-antibiotics-08-00114}
==============

In this study, combinations of protein and nucleic acid synthesis inhibitors were evaluated in order to understand their systematic drug interaction patterns. Determination of the mechanisms of action of drug molecules within antibiotic combinations is crucial for better selection of synergistic drug pairs. Detailed mechanistic studies should be conducted with a broader sample size in order to better understand drug interaction patterns.
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![Distributions of alpha values of pairwise drug combinations, which represent synergistic or antagonistic interactions. Negative values show synergistic interactions whereas positive values show antagonistic interactions of combinations of (**A**) nucleic acid synthesis inhibitors (NN), (**B**) combinations of both nucleic acid synthesis and protein synthesis inhibitors (PN), and (**C**) protein synthesis inhibitors (PP).](antibiotics-08-00114-g001){#antibiotics-08-00114-f001}

antibiotics-08-00114-t001_Table 1

###### 

List of antibiotics used in the study with minimum inhibitory concentration (MIC) values.

  Compounds         Abbreviation   Mechanism of Action                                      MIC/LB (mg/mL)
  ----------------- -------------- -------------------------------------------------------- ----------------
  Amikacin          AMK            Protein synthesis, 30S inhibition                        13
  Gentamicin        GEN            Protein synthesis, 30S inhibition                        7
  Tobramycin        TOB            Protein synthesis, 30S inhibition                        0.7
  Tetracycline      TET            Protein synthesis, 30S inhibition                        5
  Spectinomycin     SPE            Protein synthesis, 30S inhibition                        2
  Clarithromycin    CLA            Protein synthesis, 50S inhibition                        9
  Erythromycin      ERY            Protein synthesis, 50S inhibition                        15
  Chloramphenicol   CHL            Protein synthesis, 50S inhibition                        3.5
  Fusidic acid      FUS            Elongation factor, protein synthesis inhibition          80
  Mupirocin         MUP            Isoleucyl transfer, RNA (tRNA) synthetase inhibition     0.4
  Roxithromycin     ROX            Protein synthesis, 50S inhibition                        0.3
  Ciprofloxacin     CIP            DNA gyrase inhibition                                    0.05
  Levofloxacin      LEV            DNA gyrase inhibition                                    0.01
  Nalidixic acid    NAL            DNA gyrase inhibition                                    8
  Trimethoprim      TRI            Folic acid biosynthesis inhibition                       1.5
  Rifampicin        RIF            RNA polymerase inhibition                                0.5
  5-Fluorouracil    5FU            Inhibition of the formation of thymidylate from uracil   2

antibiotics-08-00114-t002_Table 2

###### 

Mann--Whitney U test for evaluation of alpha scores between different antibiotic groups. NN represents the pairwise combinations of nucleic acid synthesis mechanism-related antibiotics, PP represents the pairwise combinations of protein synthesis mechanism-related antibiotics, and PN represents the pairwise combinations of protein synthesis and nucleic acid synthesis mechanism-related antibiotics. Significance level is \<0.05.

  Combination Type   N       Min       Q1                  Median       Q3       Max
  ------------------ ------- --------- ------------------- ------------ -------- ---------
  **PP**             55      −2.4      −0.89               −0.25        0.72     4.5
  **NN**             15      −1.5      −0.07               2.51         3.45     4.5
                     **U**   **Z**     **Prob \> \|U\|**                         
                     214     −2.8      0.004                                     
                     **N**   **Min**   **Q1**              **Median**   **Q3**   **Max**
  **PN**             66      −1.5      −0.25               0.87         2.33     4.67
  **NN**             15      −1.5      −0.07               2.51         3.45     4.52
                     **U**   **Z**     **Prob \> \|U\|**                         
                     385     −1.33     0.18                                      
                     **N**   **Min**   **Q1**              **Median**   **Q3**   **Max**
  **PN**             66      −1.52     −0.25               0.87         2.33     4.67
  **PP**             55      −2.42     −0.89               −0.25        0.72     4.52
                     **U**   **Z**     **Prob \> \|U\|**                         
                     2552    3.83      1.26× 10^−4^                              

antibiotics-08-00114-t003_Table 3

###### 

Detailed pairwise drug interactions and alpha scores.

  DRUG PAIR   ALPHA   1\. DRUG   2\. DRUG   DRUG PAIR   ALPHA   1\. DRUG   2\. DRUG
  ----------- ------- ---------- ---------- ----------- ------- ---------- ----------
  PN          −0.03   AMK        CIP        PP          1.52    AMK        ROX
  PN          0.55    AMK        LEV        PP          2.8     AMK        CHL
  PN          0.87    AMK        NAL        PP          −0.45   AMK        CLA
  PN          1.34    AMK        RIF        PP          1.34    AMK        ERY
  PN          −0.35   AMK        TRI        PP          −0.67   AMK        FUS
  PN          −0.68   AMK        5FU        PP          0.65    AMK        GEN
  PN          1.94    CHL        CIP        PP          2.12    AMK        SPE
  PN          4.67    CHL        LEV        PP          0.68    AMK        TET
  PN          2.56    CHL        NAL        PP          0.89    AMK        TOB
  PN          0.36    CHL        RIF        PP          0.05    AMK        MUP
  PN          2.43    CHL        TRI        PP          −0.68   CHL        CLA
  PN          −1.52   CHL        5FU        PP          −0.89   CHL        ERY
  PN          2.57    CLA        LEV        PP          −0.92   CHL        FUS
  PN          2.1     CLA        NAL        PP          1.87    CHL        GEN
  PN          −0.56   CLA        RIF        PP          −0.56   CHL        SPE
  PN          2.32    CLA        TRI        PP          −0.92   CHL        TET
  PN          −0.89   CLA        5FU        PP          3.21    CHL        TOB
  PN          2.36    CIP        CLA        PP          −0.26   CHL        ROX
  PN          1.35    CIP        ERY        PP          −0.56   CHL        MUP
  PN          1.12    CIP        FUS        PP          −0.66   CLA        ERY
  PN          1.34    CIP        GEN        PP          −1.67   CLA        FUS
  PN          3.78    CIP        SPE        PP          0.30    CLA        GEN
  PN          4.12    CIP        TET        PP          0.25    CLA        SPE
  PN          2.13    CIP        MUP        PP          −0.89   CLA        TET
  PN          3.12    CIP        TOB        PP          0.36    CLA        TOB
  PN          3.46    LEV        SPE        PP          −1.11   CLA        MUP
  PN          2.95    LEV        TET        PP          −0.25   CLA        ROX
  PN          2.64    LEV        TOB        PP          −2.42   ERY        FUS
  PN          0.76    LEV        ERY        PP          0.23    ERY        GEN
  PN          1.2     LEV        FUS        PP          0.13    ERY        SPE
  PN          −0.21   LEV        ROX        PP          −0.90   ERY        TET
  PN          0.35    LEV        GEN        PP          1.0     ERY        TOB
  PN          2.45    LEV        MUP        PP          −0.81   ERY        MUP
  PN          2.1     ERY        NAL        PP          −0.35   ERY        ROX
  PN          0.16    ERY        RIF        PP          0.37    FUS        GEN
  PN          0.89    ERY        TRI        PP          0.47    FUS        SPE
  PN          −0.52   ERY        5FU        PP          −0.89   FUS        TET
  PN          0.67    FUS        NAL        PP          0.35    FUS        TOB
  PN          −0.76   FUS        RIF        PP          −0.76   FUS        MUP
  PN          1.54    FUS        TRI        PP          −1.53   FUS        ROX
  PN          0.54    FUS        5FU        PP          2.21    GEN        SPE
  PN          1.65    GEN        RIF        PP          −0.70   GEN        TET
  PN          0.76    GEN        TRI        PP          −0.51   GEN        TOB
  PN          1.98    GEN        5FU        PP          0.04    GEN        ROX
  PN          0.45    GEN        NAL        PP          −0.74   GEN        MUP
  PN          2.90    NAL        SPE        PP          0.72    SPE        TET
  PN          3.32    NAL        TET        PP          4.52    SPE        TOB
  PN          2.78    NAL        TOB        PP          −1.87   SPE        ROX
  PN          −0.89   NAL        ROX        PP          −1.70   SPE        MUP
  PN          0.87    NAL        MUP        PP          1.10    TET        TOB
  PN          −1.36   ROX        5FU        PP          −1.98   TET        ROX
  PN          −1.10   ROX        RIF        PP          −1.93   TET        MUP
  PN          −1.23   ROX        TRI        PP          1.12    ROX        MUP
  PN          0.56    ROX        CIP        PP          0.66    ROX        TOB
  PN          0.54    RIF        SPE        PP          0.72    TOB        MUP
  PN          −0.54   RIF        TET        NN          4.12    5FU        TRI
  PN          3.43    RIF        TOB        NN          3.53    5FU        NAL
  PN          0.45    RIF        MUP        NN          4.52    5FU        LEV
  PN          1.45    TRI        SPE        NN          3.13    5FU        RIF
  PN          2.23    TRI        TET        NN          3.45    5FU        CIP
  PN          0.45    TRI        TOB        NN          2.46    NAL        CIP
  PN          −0.46   TRI        MUP        NN          −0.05   NAL        RIF
  PN          −0.98   5FU        SPE        NN          2.82    NAL        TRI
  PN          0.74    5FU        MUP        NN          −1.52   NAL        LEV
  PN          −0.79   5FU        TOB        NN          −0.07   LEV        CIP
  PN          −0.54   5FU        TET        NN          2.89    LEV        RIF
                                            NN          −0.81   LEV        TRI
                                            NN          −0.67   TRI        CIP
                                            NN          0.29    TRI        RIF
                                            NN          2.51    CIP        RIF
